Similarly, the new drug known as checkpoint inhibitors allows the immune system of the patient in order to destroy the deadly cancerous cells.
The therapy has been hailed as one of the biggest advances in decades after research found that patients lived longer, with fewer tumours returning.
A total of 781,000 patients are diagnosed with lung cancer every year, giving it the highest incidence rate among China's malignant tumours, according to the National Cancer Center (NCC).
Gandhi wondered, Would using immunotherapy earlier in treatment, alongside chemotherapy, do more for patients?
Combining an immunotherapy drug with chemotherapy almost doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed. The immune-activating drug was a checkpoint inhibitor called pembrolizumab, or Keytruda, made by Merck, which paid for the study. The study was published Monday in the New England Journal of Medicine.More news: Apple (AAPL) Position Reduced by Stock Yards Bank & Trust Co
The Framework is the result of a four-year collaborative process involving cancer specialists and other health professionals, health service providers and consumers across Australia. "We have patients on these immunotherapies are alive more than eight years". Another had to stop because of side effects after only two or three months, but is still well two years later. Their tumors lacked certain mutations that would have made them eligible for other, "targeted" treatments.
Two thirds were given immunotherapy drugs combined with chemotherapy while... Median survival is met when 50% of the patients die.
The estimated survival at 12 months was 69.2 percent in the group that received immunotherapy, and 49.4 percent in those who did not.
The study, a phase III clinical trial testing treatment effectiveness and side effects, included 616 patients at 118 medical facilities around the globe.